FORAGER-1 tox profile markedly improved compared to pan-isoform FGFR inhibitors with diarrhea, transaminitis, and fatigue most common TEAEs and no retinopathy events observed. Triplet EV P vepu in first line mUC showed 4 of 5 objective responses. Ph 3 FORAGER-2 study opening soon
#ESMO2025 exciting update on FORAGER-1 trial of the FGFR3 isoform-specific inhibitor vepugratinib in heavily pretreated FGFR3-altered mUC by Alexandra Drakaki. ORR 34% at the optimal 200 mg bid dose, DCR 94% and 61% of responses sustained at 8 mo median f/u.
